Thrombolytics for Intermediate-Risk Pulmonary Embolisim: Are We There Yet?

Name: Thrombolytics for Intermediate-Risk Pulmonary Embolisim: Are We There Yet?
Uploaded: 2015-01-07T00:00:00+00:00
Description: Jay Giri, MD, considers the evolving landscape of blood thinners for use in pulmonary embolism therapy, including thrombolytics, standard anticoagulation, and the new tissue plasminogen activator tenecteplase.

In this video, Jay GIri, MD, Director, Peripheral Intervention at Penn Medicine, offers an overview of thrombolytic therapy for pulmonary embolism. Dr Giri’s discussion includes a comparison of thrombolytics to standard anticoagulation therapy, an overview of the PEITHO trial of the tissue plasminogen activator tenecteplase, catheter-directed thrombolysis and age-specific recommendations for each treatment.